Retrospective Study on Anti-cancer Therapy for Gastric Cancer Patients Complicated With Bleeding
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 200
- 主要终点
- Overall survival (OS)
研究概览
简要总结
To investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
详细描述
We will retrospectively enroll patients diagnosed with advanced or metastatic gastric cancer at the Department of Medical Oncology and Radiation Sickness of Peking University Third Hospital. The retrospective study aims to investigate the impact of bleeding on treatment-related adverse events (TRAEs) for gastric cancer patients receiving systematic anticancer treatment, assess the influence of bleeding on the survival of patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients older than 18 years;
- •A histologically confirmed diagnosis of advanced or metastatic gastric cancer;
- •The initial anticancer treatment was systematic therapy, including chemotherapy, targeted therapy or immune checkpoint inhibitor (ICI);
- •No history of gastrectomy before systematic therapy.
排除标准
- •Incompletable clinical data;
- •Siewert I type esophagus cancer.
研究组 & 干预措施
Control group
Gastirc cancer without bleeding at first diagnosis
干预措施: systematic therapy (Drug)
Test group
Gastirc cancer with bleeding at first diagnosis
干预措施: systematic therapy (Drug)
结局指标
主要结局
Overall survival (OS)
时间窗: from date of the first cycle of systematic therapy to death from any cause，assessed up to 120 months
OS was defined as the time from the first cycle of systematic therapy to death from any cause.
次要结局
未报告次要终点
研究者
Yanhong Yao
Department of Medical Oncology and Radiation Sickness
Peking University Third Hospital